• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday

    2/5/24 10:32:52 AM ET
    $CNA
    $CORZ
    $CTLT
    $DWAC
    Property-Casualty Insurers
    Finance
    Finance: Consumer Services
    Finance
    Get the next $CNA alert in real time by email

    U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday.

    Shares of The Estée Lauder Companies Inc. (NYSE:EL) rose sharply during Monday’s session after the company reported better-than-expected second-quarter financial results and announced a restructuring program, which includes an estimated net reduction of roughly 3 to 5 percent of its positions as of June 30, 2023.

    Estée Lauder shares gained 14% to $152.93 on Monday.

    Here are some other big stocks recording gains in today’s session.

    • 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) jumped 100.9% to $35.13 after the company announced interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet AMD patients with severe disease activity and a high treatment burden.
    • Everbridge, Inc. (NASDAQ:EVBG) shares surged 18.2% to $28.13 after the company announced it will be acquired by Thoma Bravo for $1.5 billion.
    • MorphoSys AG (NASDAQ:MOR) rose 15.7% to $12.81.
    • Core Scientific, Inc. (NASDAQ:CORZ) jumped 10.3% to $3.29. Core Scientific produced 13,762 Bitcoin in 2023.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) rose 10.1% to $44.68.
    • Catalent, Inc. (NYSE:CTLT) climbed 10% to $59.97 after the company announced it will be acquired by Novo Holdings.
    • Napco Security Technologies, Inc. (NASDAQ:NSSC) rose 8.5% to $38.86 following second-quarter results.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) jumped 7.6% to $623.84.
    • ON Semiconductor Corporation (NASDAQ:ON) gained 7.3% to $75.97 after the company reported better-than-expected fourth-quarter financial results.
    • Elanco Animal Health Incorporated (NYSE:ELAN) surged 6% to $15.61 after the company announced the sale of its aqua business to Merck Animal health for $1.3 billion.
    • Haynes International, Inc. (NASDAQ:HAYN) gained 6% to $59.49 as the company penned a deal to be acquired by North American Stainless, a wholly owned subsidiary of Acerinox, for an enterprise value of about $970 million.
    • CNA Financial Corporation (NASDAQ:CNA) gained 5.2% to $45.59 after it reported fourth-quarter FY23 results.
    • Eli Lilly and Company (NYSE:LLY) rose 5.2% to $702.38. Eli Lilly and Company is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 6, 2024.
    • Tyson Foods, Inc. (NYSE:TSN) gained 3.5% to $58.32 after the company reported better-than-expected first-quarter financial results and issued guidance.

     

    Now Read This: Mastercard, American Express And A Tech Stock: CNBC's 'Final Trades'

    Get the next $CNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNA
    $CORZ
    $CTLT
    $DWAC

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Core Scientific Inc.
    $CORZ
    3/3/2026$23.00Hold → Buy
    Needham
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    ON Semiconductor Corporation
    $ON
    2/12/2026$75.00Equal Weight
    Barclays
    Estee Lauder Companies Inc.
    $EL
    2/10/2026$106.00Buy → Hold
    HSBC Securities
    ON Semiconductor Corporation
    $ON
    2/10/2026Buy → Hold
    The Benchmark Company
    Estee Lauder Companies Inc.
    $EL
    2/6/2026$120.00Neutral → Buy
    Citigroup
    More analyst ratings

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sternlicht Barry S

    4 - ESTEE LAUDER COMPANIES INC (0001001250) (Issuer)

    3/17/26 4:42:31 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Director Long Annabelle Yu

    4 - ESTEE LAUDER COMPANIES INC (0001001250) (Issuer)

    3/17/26 4:41:55 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Director Lauder William P

    4 - ESTEE LAUDER COMPANIES INC (0001001250) (Issuer)

    3/17/26 4:42:06 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    $CNA
    $CORZ
    $CTLT
    $DWAC
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Core Scientific Inc.

    10-K/A - Core Scientific, Inc./tx (0001839341) (Filer)

    3/18/26 5:14:20 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    SEC Form S-8 filed by 4D Molecular Therapeutics Inc.

    S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

    3/18/26 4:55:31 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by 4D Molecular Therapeutics Inc.

    10-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

    3/18/26 4:29:45 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

    For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeksINDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise. The trial enrolled adults diagn

    3/19/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

    Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial 2-year data in H2 20264D-150 DME global Phase 3 trial initiation expected in Q3 2026$514 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and dis

    3/18/26 4:05:00 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Supermicro Advances Enterprises' Adoption of Accelerated Computing Across AI Factory, Data Center, and Edge with Expanded Portfolio Featuring NVIDIA RTX PRO Blackwell Server Edition GPUs

    New systems available in multiple form factors based on Supermicro's modular Building Block Solutions® to enable right-sizing for space, power, and thermally-restricted environments commonly found in enterprise and edge data centers.Support for the new NVIDIA RTX PRO™ 4500 Blackwell Server Edition GPU and NVIDIA Vera CPU enables new levels of multi-workload acceleration and efficiency across data center, cloud, and edge deployments.Supermicro's NVIDIA-Certified Systems are NVIDIA accelerated application-ready and guarantee compatibility with NVIDIA RTX PRO Blackwell GPUs, NVIDIA networking, and NVIDIA software.SAN JOSE, Calif., March 18, 2026 /PRNewswire/ -- Super Micro Computer, Inc. (NASDA

    3/18/26 9:05:00 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    $CNA
    $CORZ
    $CTLT
    $DWAC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Core Scientific upgraded by Needham with a new price target

    Needham upgraded Core Scientific from Hold to Buy and set a new price target of $23.00

    3/3/26 10:31:14 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyson Foods to Hold Annual Meeting of Shareholders

    SPRINGDALE, Ark., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE:TSN) will hold its Annual Meeting of Shareholders on Thursday, February 5, 2026 at 11:00 a.m. Eastern time (10 a.m. Central time) at Tyson Foods, 2008 South Thompson Street, Springdale, Arkansas 72764. For shareholders attending in person, an admission ticket is required. Cameras, video and audio recording equipment, as well as large bags are not permitted. Please see our proxy statement, filed on December 17, 2025, for further information. WebcastA link for the webcast of the meeting is available on the Tyson Investor Relations website at https://ir.tyson.com. Audio OnlyParticipants may join the audio-only versi

    1/12/26 4:15:00 PM ET
    $TSN
    Meat/Poultry/Fish
    Consumer Staples

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Financials

    Live finance-specific insights

    View All

    Core Scientific Announces Fourth Quarter Fiscal Year 2025 Results

    Key Highlights New Top-market Site: Announced an agreement to expand into Hunt County, Texas, which is expected to support ~430 MW of gross power capacity, with an approved ERCOT interconnection ramp schedule. Power Expansion at Existing Locations: Increased gross power capacity by ~300 MW across Dalton, Georgia and Pecos, Texas. Continued Execution on CoreWeave Contract: To date, energized ~350 MW of power and remain on track to deliver ~590 MW by early 2027. Core Scientific, Inc. (NASDAQ:CORZ), a leader in digital infrastructure for high-density colocation services, today announced financial results for the fourth quarter of 2025. "We're now past the halfway point on our e

    3/2/26 4:10:00 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Core Scientific, Inc. Schedules Fourth Quarter Fiscal Year 2025 Earnings Release, Conference Call and Webcast

    Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation, today announced it will release its fourth quarter and fiscal year 2025 financial results after the financial markets close on Monday, March 2, 2026. Management will host a conference call and live audio webcast to discuss the results at 3:30 p.m. Central Time. Hosting the call and webcast to review results for the fourth quarter and fiscal year 2025 will be Adam Sullivan, Chief Executive Officer, Matt Brown, Chief Operating Officer, Jim Nygaard, Chief Financial Officer, and Jon Charbonneau, Vice President, Investor Relations. Conference Call and Webc

    2/23/26 7:00:00 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    $CNA
    $CORZ
    $CTLT
    $DWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Estee Lauder Companies Inc.

    SC 13D/A - ESTEE LAUDER COMPANIES INC (0001001250) (Subject)

    12/10/24 6:06:03 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Estee Lauder Companies Inc.

    SC 13D/A - ESTEE LAUDER COMPANIES INC (0001001250) (Subject)

    12/9/24 5:30:41 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Estee Lauder Companies Inc.

    SC 13D/A - ESTEE LAUDER COMPANIES INC (0001001250) (Subject)

    12/9/24 5:30:28 PM ET
    $EL
    Package Goods/Cosmetics
    Consumer Discretionary